The durability of twice-daily insulin lispro low mixture compared to once-daily insulin glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control

Trial Profile

The durability of twice-daily insulin lispro low mixture compared to once-daily insulin glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Insulin glargine; Insulin lispro; Insulin neutral protamine lispro/insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DURABLE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 Sep 2010 Results were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 01 May 2010 Results of the intensification substudy published in Clinical Therapeutics.
    • 26 Jan 2010 Actual patient number changed from 2091 to 2133 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top